Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Praxis Precision Medicines, Inc. (NASDAQ: PRAX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Praxis is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, and its filings offer detailed insight into the development and financing of its precision neuroscience portfolio.
Through Forms 8-K, Praxis reports material events such as topline clinical results, regulatory interactions and capital markets transactions. Recent 8-K filings describe positive Phase 3 Essential3 data for ulixacaltamide in essential tremor, EMBOLD study outcomes for relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs), and RADIANT study data for vormatrigine in focal onset seizures and generalized epilepsy. Other 8-Ks outline pre-New Drug Application (NDA) meetings with the U.S. Food and Drug Administration (FDA), alignment on registrational pathways for elsunersen in early-onset SCN2A-DEE, and details of underwritten public offerings and at-the-market equity programs.
Investors can also use this page to monitor filings related to Praxis’ common stock listing on The Nasdaq Global Select Market under the symbol PRAX, shareholder meeting results, and executive compensation or governance matters disclosed in proxy-related documents. As Praxis advances ulixacaltamide, vormatrigine, relutrigine and elsunersen, its periodic and current reports are expected to discuss clinical progress, regulatory designations, risk factors and use of proceeds from financings.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the significance of each PRAX filing. Real-time updates from EDGAR, combined with accessible explanations of complex disclosures, make this page a practical starting point for analyzing Praxis Precision Medicines’ regulatory and financial reporting history.
Praxis Precision Medicines is a clinical-stage CNS-focused biopharmaceutical company using two platforms, Cerebrum™ (small molecules) and Solidus™ (ASOs), to develop precision therapies for neurological disorders driven by neuronal excitation–inhibition imbalance.
The company has four clinical-stage programs: ulixacaltamide for essential tremor with positive Phase 3 data and a submitted NDA; relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies with a submitted NDA and ongoing broader Phase 3; vormatrigine for common epilepsies in the multi-study ENERGY program; and elsunersen, an ASO for SCN2A-DEE in the EMBRAVE and EMBRAVE3 studies.
Praxis highlights extensive patent coverage across its platforms, relies on CDMOs for manufacturing, and operates under standard FDA drug-development regulations. Key risks include ongoing operating losses, future capital needs, uncertain and lengthy regulatory pathways, clinical and enrollment risk, competitive pressure, heavy reliance on collaborators and licenses (including Ionis and RogCon), intellectual property challenges, cybersecurity threats, and significant stock-price volatility.
Praxis Precision Medicines reported a larger net loss for 2025 while advancing a late-stage CNS portfolio and significantly strengthening its balance sheet. The company posted a full-year net loss of $303.3 million, up from $182.8 million in 2024, driven mainly by higher research and development spending of $267.1 million as multiple programs advanced.
Cash, cash equivalents and marketable securities were $926.1 million as of December 31, 2025, compared to $469.5 million a year earlier, and together with $621.2 million in net proceeds from a January 2026 follow-on offering are expected to fund operations into 2028. The company submitted two NDAs to the FDA, for ulixacaltamide in essential tremor and relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies, and highlighted two additional late-stage programs, vormatrigine and elsunersen, with topline results expected in the first half of 2026.
Praxis Precision Medicines, Inc. received an amended Schedule 13G from investment entities affiliated with Point72 and Steven A. Cohen reporting beneficial ownership of 6.1% of its common stock as of December 31, 2025. The filing shows shared voting and dispositive power over 1,569,309 shares of common stock, including 511,030 shares issuable upon exercise of warrants and 500,000 shares issuable upon exercise of call options held by Point72 Associates. The reporting persons certify that the securities were not acquired for the purpose of changing or influencing control of Praxis Precision Medicines.
Perceptive Advisors LLC and affiliated reporting persons disclosed beneficial ownership of 1,995,986 shares of Praxis Precision Medicines, Inc. common stock, representing 7.2% of the class. The shares are held directly by Perceptive Life Sciences Master Fund, Ltd., with Perceptive Advisors as investment manager and Joseph Edelman as managing member.
The ownership percentage is based on 27,738,892 Praxis common shares outstanding as reported in a Prospectus Supplement filed under Rule 424(b)(5) on January 7, 2026. The reporting persons report shared voting and dispositive power over all 1,995,986 shares and certify the holdings are not for the purpose of changing or influencing control of Praxis.
Praxis Precision Medicines, Inc. received an ownership report from Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd. Together, the reporting persons state they beneficially own 1,255,162 shares of Praxis common stock, representing 5% of the class as of 12/31/2025.
Orbis Investment Management Ltd reports sole voting and dispositive power over 1,252,573 shares, while Allan Gray Australia Pty Ltd reports sole voting and dispositive power over 2,589 shares. Both firms are non‑U.S. institutions equivalent to investment advisers and certify that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Praxis.
Praxis Precision Medicines, Inc. received an amended Schedule 13G/A from Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross reporting their beneficial ownership in the company’s common stock.
The Reporting Persons collectively hold 965,313 shares of common stock, representing 3.83% of the class, based on 25,195,092 shares outstanding as of December 31, 2025. All shares are held with shared voting and dispositive power and are reported as being acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Praxis.
Praxis Precision Medicines director Stuart A. Arbuckle reported new equity awards in the company. On February 6, 2026, he received 688 restricted stock units and 478 restricted stock units, each at a price of $0, with vesting tied to 2026 and 2027 service and the 2026 annual meeting. Each unit represents one share of common stock, settled only in shares. He was also granted a stock option for 224 shares at an exercise price of $319.57, vesting in monthly installments from February 26, 2026 until the earlier of June 26, 2026 or the 2026 annual meeting. Following these grants, he beneficially owns 1,166 shares of common stock and 224 stock options, all held directly.
Praxis Precision Medicines director Jeffrey B. Kindler reported new equity awards. On February 6, 2026, he received 688 restricted stock units that vest in two equal annual installments on the first two anniversaries of January 8, 2026.
He was also granted 478 restricted stock units that vest in a single installment on the earlier of June 26, 2026 or the company’s 2026 annual shareholder meeting. Following these grants, he directly holds 1,166 shares of common stock tied to these awards.
In addition, Kindler received a stock option for 224 shares of common stock with a stated exercise price of $319.57 per share, vesting in equal monthly installments from February 26, 2026 through the earlier of June 26, 2026 or the 2026 annual meeting.
Praxis Precision Medicines, Inc. filed an amended current report to update board committee assignments and its Non-Employee Director Compensation Policy, effective February 6, 2026. New directors Jeffrey B. Kindler and Stuart A. Arbuckle, previously elected as Class II directors, received formal committee roles.
Mr. Kindler was appointed to the Audit Committee and the Nominating and Corporate Governance Committee, while Mr. Arbuckle joined the Compensation Committee and the Science and Technology Committee. The amended policy provides Outside Directors a $50,000 annual cash retainer for board service plus additional annual retainers for chair and member roles on key committees, paid quarterly in arrears and prorated for partial service.
The policy also grants equity compensation under the company’s equity plan, including initial restricted stock unit awards and, when applicable, pro rata options and RSUs based on a Black-Scholes valuation and Fair Market Value, along with recurring annual option and RSU awards that vest over one or two years or accelerate upon a Sale Event.
FMR LLC filed a Schedule 13G reporting a passive ownership stake in Praxis Precision Medicines Inc. common stock. FMR LLC and Abigail P. Johnson are reported as beneficial owners of 1,353,275.05 shares, representing 5.4% of the outstanding common stock as of the reporting date.
The securities are certified as acquired and held in the ordinary course of business, not to change or influence control of the company. One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the class.